Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDEPENDENCE: Luspatercept in Myelofibrosis
NCT04717414Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Feb 2021
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
A Phase 3 trial of luspatercept in myelofibrosis (MF), anemia, sponsored by Celgene Corporation. Started Feb 2021; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelofibrosis (MF)anemia
Beyond the preview
Go deeper on NCT04717414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717414.